Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP RANDOMET 2017
2023-508926-91-00Phase 3Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of vincristine, actinomycin D, doxorubicin, carboplatin and etoposide in Wilms' tumor and renal cell carcinoma (RCC) (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Planned start Dec 2019; status: authorised.
02
Drugs
vincristineactinomycin Ddoxorubicincarboplatinetoposide
03
Conditions
Wilms' tumorrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-508926-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508926-91-00.